Modular ROCK™platform enabling multi-specific NK / T-cell bi-and tri-specific Abs. Aug 2018 deal with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics through application of ROCK platform. Lead NK cell engager AFM13 (CD30/CD16A) in Ph1b combo w/ Keytruda in Hodgkins and Ph2a (mono) in CD30(+) lymphoma including TCL. T-cell engager AFM11 (CD19/CD3) in 2 dose escalation studies in ALL and NHL.
Im Neuenheimer Feld 582
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by